S-1: Cartesian Therapeutics Files for Resale of 6.5 Million Shares of Common Stock

Cartesian Therapeutics has filed a registration statement for the resale of up to 6.5 million shares of its common stock by selling stockholders.

Summary

• Cartesian Therapeutics has filed a registration statement for the resale of up to 6,501,150 shares of its common stock.
• The shares are being offered by selling stockholders and include 3,563,247 shares of common stock and 2,937,903 shares of common stock issuable upon conversion of Series B Preferred Stock.
• The selling stockholders may sell the shares on any national securities exchange, in the over-the-counter market, or through privately negotiated transactions.
• The company will not receive any proceeds from the sale of these shares.
• The filing includes details about the company's business, financial condition, management, and risk factors.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment as it primarily describes a financial transaction (resale of shares) and outlines associated risks. It does not express strong positive or negative views.

Risks

• The prospectus highlights various risk factors associated with investing in the company's securities, including risks related to drug development, manufacturing, dependence on third parties, commercialization, financial position, need for additional capital, and intellectual property.

Future Outlook

The selling stockholders will determine when and how they will dispose of the shares of Common Stock and shares of Common Stock issuable upon conversion of Series B Preferred Stock registered under this prospectus for resale.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors beyond mentioning the competitive landscape in the 'Risk Factors' section.

Legal Proceedings

• On February 21, 2024, Paul Wymer, a purported stockholder of our Company, filed an action against us and members of our Board of Directors in the U.S. District Court for the Southern District of New York, titled Wymer v. Cartesian Therapeutics, Inc., et al., No. 24-cv-01288.
• The complaint alleged that the defendants violated Sections 14(a) and 20(a) of the Exchange Act by failing to disclose purportedly material information to our stockholders in our Preliminary and Definitive Proxy Statements filed on January 31, 2024, and February 14, 2024, respectively, in connection with the solicitation of stockholder approval of a proposal to convert our Series A Preferred Stock into our Common Stock, subject to certain beneficial ownership limitations (the Series A Conversion Proposal).
• This action was voluntarily dismissed on March 11, 2024.
• On February 7, 2024, Justin Sloan, a purported stockholder of our Company, filed a putative class action on behalf of himself and similarly situated stockholders of the Company against our Company and members of our Board of Directors in the Court of Chancery of the State of Delaware, titled Sloan v. Barabe, et al., No. 2024-0105.
• The complaint alleged that the individual defendants breached their fiduciary duties by failing to disclose purportedly material information to our Companys stockholders in our Preliminary Proxy Statement filed on January 31, 2024 in connection with the solicitation of stockholder approval of the Series A Conversion Proposal.
• This action was subsequently dismissed on March 13, 2024.
• On August 3, 2020, a stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Companys Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al.
• On August 1, 2022, the Court entered an Order and Final Judgment which dismissed the action, and all claims contained therein, with prejudice.

Related Party Transactions

• Dr. Timothy A. Springer, a member of our Board of Directors, and TAS Partners LLC, an affiliate of Dr. Springer, and Seven One Eight Three Four Irrevocable Trust, a trust associated with Dr. Murat Kalayoglu, a co-founder and the former chief executive officer of Old Cartesian, who joined our Board of Directors effective immediately after the effective time of the Merger, providing for the November 2023 Private Placement.
• In the November 2023 Private Placement, we issued and sold an aggregate of 149,330.115 shares of Series A Preferred Stock for an aggregate purchase price of $60.25 million.

Stakeholder Impact

• The resale of shares by selling stockholders could potentially impact the share price of Cartesian Therapeutics, affecting current shareholders.
• The company will not receive any proceeds from the sale of the Resale Shares covered hereby.

Next Steps

• The selling stockholders may sell the Resale Shares on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale, on the over-the-counter market, in one or more transactions otherwise than on these exchanges or systems, such as privately negotiated transactions, or using a combination of these methods, and at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices.

Key Dates

Keywords

common stock, resale, registration statement, selling stockholders, Series B Preferred Stock, Cartesian Therapeutics, RNAC, securities